Robert M. Califf

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)

Robert M. Califf, Kirkwood F. Adams, William J. McKenna et al. · American Heart Journal · 1997 · 654 citations

Heart Failure, Epoprostenol Therapy, Structural Heart Disease +8

Racial Variation in the Use of Coronary-Revascularization Procedures — Are the Differences Real? Do They Matter?

Eric D. Peterson, Linda K. Shaw, Elizabeth R. DeLong et al. · New England Journal of Medicine · 1997 · 552 citations · Full text

The Evolution of Medical and Surgical Therapy for Coronary Artery Disease

Robert M. Califf · JAMA · 1989 · 301 citations

Heart Failure, Improved Survival, Surgery +16

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania.

A. Michael Lincoff, Robert M. Califf, Keaven M. Anderson et al. · Journal of the American College of Cardiology · 1997 · 207 citations

C7e3 Fab, Percutaneous Coronary Intervention, Thrombosis +10

Age and outcome after acute coronary syndromes without persistent ST-segment elevation

David Hasdai, David R. Holmes, Douglas A. Criger et al. · American Heart Journal · 2000 · 72 citations

Cardiovascular Disease, Atherosclerosis, Persistent St-segment Elevation +9